Cancer is the second-leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives innovations that revolutionize cancer care—innovations like immunotherapy. Immunotherapy fights cancer using the body’s own immune system, often by boosting the performance of specialized adaptive immune cells called T cells.

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute scientists reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells and suggests a therapeutic countermeasure: Change what the cancer displays on its surface so the immune system can recognize the tumor.

The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects, developing more focused strategies based on these mechanistic findings could meet an important need in cancer therapy.

Cytological tests are a common method of screening for cancer cells in stained cell samples. Using a microscope, pathologists examine cells collected from bodily fluids, looking for telltale signs of malignancy, like enlarged nuclei or abnormal cell shapes. Owing to their minimally invasive nature, these tests are widely used for early cancer screening and diagnosis.

Type 2 diabetes increases the risk of chronic kidney disease, making prevention of kidney failure a key part of treatment. Newer diabetes medications, including GLP-1s and SGLT2 inhibitors, can reduce the risk of kidney disease, but previous studies have included large proportions of patients who already had signs of kidney damage, making it unclear whether the findings applied to patients without kidney damage.

Virtually all high-grade, aggressive gliomas in adults accumulate massive amounts of a metabolite called guanidinoacetate (GAA) that overstimulates nearby neurons and promotes tumor growth, according to new research from scientists at Children’s Medical Center Research Institute at UT Southwestern (CRI) published in Cell.

A little-known chronic lung disease is silently emerging as a growing public health threat in the U.S. and around the world. Nontuberculous mycobacteria—a group of 200 known environmental bacteria found in soil and water, including household plumbing—can cause chronic, tuberculosis-like lung infections. NTM lung disease afflicts as many as 300,000 Americans a year.